Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Vulvar Cancer Overview 6 Therapeutics Development 7 Pipeline Products for Vulvar Cancer - Overview 7 Pipeline Products for Vulvar Cancer - Comparative Analysis 8 Vulvar Cancer - Therapeutics under Development by Companies 9 Vulvar Cancer - Therapeutics under Investigation by Universities/Institutes 10 Vulvar Cancer - Pipeline Products Glance 11 Clinical Stage Products 11 Vulvar Cancer - Products under Development by Companies 12 Vulvar Cancer - Products under Investigation by Universities/Institutes 13 Vulvar Cancer - Companies Involved in Therapeutics Development 14 ISA Pharmaceuticals B.V. 14 Ono Pharmaceutical Co., Ltd. 15 Oryx GmbH & Co. KG 16 PDS Biotechnology Corporation 17 Vulvar Cancer - Therapeutics Assessment 18 Assessment by Monotherapy Products 18 Assessment by Target 19 Assessment by Mechanism of Action 21 Assessment by Route of Administration 23 Assessment by Molecule Type 25 Drug Profiles 27 Cellular Immunotherapy for HPV Associated Cancers - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 ISA-101 - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 nivolumab - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 omiganan pentahydrochloride - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 PDS-0101A - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Vicoryx - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Vulvar Cancer - Recent Pipeline Updates 43 Vulvar Cancer - Dormant Projects 69 Vulvar Cancer - Product Development Milestones 70 Featured News & Press Releases 70 Oct 05, 2011: FDA Grants ISA Pharmaceuticals Orphan Drug Designation For Treatment Of Vulvar Intraepithelial Neoplasia With ISA-HPV-SLP 70 Mar 07, 2011: ISA Pharma Receives €2.7m From Dutch Government To Further Clinical Development Of HPV-SLP Vaccine 70 Jun 02, 2010: Bachem To Supply ISA Pharmaceuticals With Finished Dosage Forms Immunotherapeutic HPV-SLP For Phase III Clinical Trials 70 Jun 02, 2010: Bachem To Supply ISA Pharmaceuticals With Finished Dosage Forms Immunotherapeutic HPV-SLP For Phase III Clinical Trials 71 Appendix 72 Methodology 72 Coverage 72 Secondary Research 72 Primary Research 72 Expert Panel Validation 72 Contact Us 72 Disclaimer 73

List of Tables Number of Products under Development for Vulvar Cancer, H1 2016 7 Number of Products under Development for Vulvar Cancer - Comparative Analysis, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Number of Products under Investigation by Universities/Institutes, H1 2016 10 Comparative Analysis by Clinical Stage Development, H1 2016 11 Products under Development by Companies, H1 2016 12 Products under Investigation by Universities/Institutes, H1 2016 13 Vulvar Cancer - Pipeline by ISA Pharmaceuticals B.V., H1 2016 14 Vulvar Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 15 Vulvar Cancer - Pipeline by Oryx GmbH & Co. KG, H1 2016 16 Vulvar Cancer - Pipeline by PDS Biotechnology Corporation, H1 2016 17 Assessment by Monotherapy Products, H1 2016 18 Number of Products by Stage and Target, H1 2016 20 Number of Products by Stage and Mechanism of Action, H1 2016 22 Number of Products by Stage and Route of Administration, H1 2016 24 Number of Products by Stage and Molecule Type, H1 2016 26 Vulvar Cancer Therapeutics - Recent Pipeline Updates, H1 2016 43 Vulvar Cancer - Dormant Projects, H1 2016 69 List of Figures Number of Products under Development for Vulvar Cancer, H1 2016 7 Number of Products under Development for Vulvar Cancer - Comparative Analysis, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Comparative Analysis by Clinical Stage Development, H1 2016 11 Assessment by Monotherapy Products, H1 2016 18 Number of Products by Targets, H1 2016 19 Number of Products by Stage and Targets, H1 2016 19 Number of Products by Mechanism of Actions, H1 2016 21 Number of Products by Stage and Mechanism of Actions, H1 2016 21 Number of Products by Routes of Administration, H1 2016 23 Number of Products by Stage and Routes of Administration, H1 2016 23 Number of Products by Molecule Types, H1 2016 25 Number of Products by Stage and Molecule Types, H1 2016 25

ISA Pharmaceuticals B.V. Ono Pharmaceutical Co., Ltd. Oryx GmbH & Co. KG PDS Biotechnology Corporation